ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / SRPT
SLS (38) XERS (64) BRVE (46) TRVI (30) ⌘ Pro Terminal →

Sarepta Therapeutics Inc. (SRPT) — RQD Stock Rating Cockpit

$18.32 -1.61% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $18.23

Sarepta Therapeutics Inc. (SRPT) carries a Roarable Rating of E (Strong Sell) with 27/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $1.97B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on SRPT Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is SRPT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Sarepta Therapeutics Inc. (NASDAQ: SRPT) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 27/100 at a spot price of $18.32 (-1.61% 1D, market cap $1.97B). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 3/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, SRPT ranks #879 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does SRPT compare to SLS and XERS in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SRPT carries a Roarable E (27/100 RQD), trailing P/E of N/A, gross margin of 96.0%, and ROIC of -35.0%. By comparison, SLS (SELLAS Life Sciences Group Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -21.8%, cap $1.95B) and XERS (Xeris Biopharma Holdings Inc.) posts a C grade (64/100 RQD, P/E N/A, ROIC 16.0%, cap $1.95B). Among the 5-stock peer group, SRPT leads on earnings multiple (N/A) while XERS leads on capital efficiency (16.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for SRPT?
▼

Per SRPT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000873303), Sarepta Therapeutics Inc. generated $1.86B in revenue (+4.3% YoY), -$713.4M in net income, and -$307.5M in free cash flow against $3.35B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $18.23 (-0.48%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (27/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.3% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510027
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E
Cash (5)Whales (8)SEC (8)Macro (3)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-14% Base Target
$26 Bull$16 Base$12 Bear
📬 FREE SRPT RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SRPT)Realized 20D OHLCV Swing Band: ±10.8%
Deterministic 5-Pillar Attribution (27/100 Composite)
🔍 WHY SRPT SCORES 27/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+8/20 pts (30% of score)

20D Institutional Volume Accumulation (±10.8% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (30% of score)

Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 4/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
19
Grade E$16.51+16.1% Next Q
Q2 (-2Q)
22
Grade E$19.17-1.5% Next Q
Q3 (-1Q)
24
Grade E$18.89-3% Next Q
Current
27
Grade E$18.32-10.3% Hist 90D α
Trajectory: E (19) → E (27)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a SRPT Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While SRPT currently carries a cautious 27/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($19.26) and Max Pain ($19.24) forces dealer call-delta covering toward $25.91.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SRPT• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “SRPT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 27%NO 73%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
50.730 Oversold · 70 Hot
ALTMAN-Z SHIELDDISTRESS RISK (<1.8)
0.20>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
4 / 99-Pt Accounting
52-WEEK LASER RANGE36% OF RANGE
L: $15$18.32H: $25
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 5 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 11 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: ERQD 11 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on SRPT

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (25)

-35.0% ROIC with 96.0% gross margin and -15.14% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (40)

Altman-Z 0.20 and Piotroski 4/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (23)

11/40 institutional & smart-money positioning score with 3/20 macro alignment.

Bull Case: Why Buyers Like SRPT
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SRPT)

  • ✓Walkthrough of SRPT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
SRPT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -16.88%▲ ASCENDING CHANNEL
2026-11-03O $19.23H $19.23L $18.32C $18.32VOL 1.32M
RES: $26.64SUP: $16.81SMA50: $19.26SMA200: $18.70
$24.25$21.65$19.06$16.47$13.88RES $26.64SUP $16.81$18.322026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SRPT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SRPT Butterfly Map → + Track SRPT →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +4.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on SRPT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SRPT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for SRPT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SRPT)

Health Care Rank #879 of 1015 ⚔️ SLS vs SRPT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SRPT vs. SLS, XERS, BRVE, TRVI)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Sarepta Therapeutics Inc. (SRPT) ranks #879 by composite RQD confidence (27/100, grade E) and #257 by equity capitalization ($1.97B). Within this direct 5-issuer industry benchmark cohort, SRPT leads on earnings valuation at N/A trailing P/E, while XERS leads on capital efficiency and profitability with 16.0% ROIC and — gross margin. XERS currently holds the highest overall quantitative score in the immediate peer group at 64/100 (C) compared with SRPT at 27/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
SRPT ACTIVE
Sarepta Therapeutics Inc.
E 27/100 — 96.0% -35.0% -1.61% $1.97B Benchmark Subject
SLS
SELLAS Life Sciences Group Inc.
D- 38/100 — — -21.8% -11.67% $1.95B /sls-vs-srpt →
XERS
Xeris Biopharma Holdings Inc.
C 64/100 — — 16.0% -5.04% $1.95B /xers-vs-srpt →
BRVE
Braveheart Bio Inc.
D 46/100 — — — -2.18% $1.94B /brve-vs-srpt →
TRVI
Trevi Therapeutics Inc.
E 30/100 — — -23.7% +0.52% $1.93B /trvi-vs-srpt →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000873303 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Sarepta Therapeutics Inc. (SRPT) reported GAAP revenue of $1.86B (+4.3% vs. FY2024 revenue of $1.79B , and +62.8% cumulative change since FY2023) , GAAP net income of -$713.4M, operating cash flow of -$205.5M, and free cash flow of -$307.5M (+10.3% YoY). On the balance sheet, SRPT closed FY2025 with $3.35B in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 4/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $1.86B -$713.4M -$205.5M -$307.5M $3.35B —
FY2024 (FY) 2024-12-31 $1.79B $235.2M -$205.8M -$342.7M $3.96B —
FY2023 (FY) 2023-12-31 $1.14B -$536.0M -$501.0M -$501.0M — —

3. SRPT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SRPT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Sarepta Therapeutics Inc. (NASDAQ: SRPT) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 27/100 at a spot price of $18.32 (-1.61% 1D, market cap $1.97B). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 3/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, SRPT ranks #879 in composite RQD confidence.

How does SRPT compare to SLS and XERS in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SRPT carries a Roarable E (27/100 RQD), trailing P/E of N/A, gross margin of 96.0%, and ROIC of -35.0%. By comparison, SLS (SELLAS Life Sciences Group Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -21.8%, cap $1.95B) and XERS (Xeris Biopharma Holdings Inc.) posts a C grade (64/100 RQD, P/E N/A, ROIC 16.0%, cap $1.95B). Among the 5-stock peer group, SRPT leads on earnings multiple (N/A) while XERS leads on capital efficiency (16.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SRPT?

Per SRPT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000873303), Sarepta Therapeutics Inc. generated $1.86B in revenue (+4.3% YoY), -$713.4M in net income, and -$307.5M in free cash flow against $3.35B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SRPT trading relative to its 50-day, 200-day, and 52-week technical levels?

SRPT last traded at $18.32 (-1.61% on volume of 1,159,406 shares), positioning the stock -4.88% below its 50-day simple moving average ($19.26) and -2.03% below its 200-day simple moving average ($18.70). Across its 52-week range of $14.68 to $24.68, SRPT sits at the 36.4% percentile with a 14-day RSI of 50.7 (NEUTRAL RANGE) and an implied next-earnings move of ±10.8% ($16.34 to $20.30).

Direct Sub-Reports: SRPT RQD Cockpit SRPT 12M Forecast SRPT Earnings & Move SRPT Dividends & DRIP SRPT Insiders & 13F SRPT Whale Options SRPT Profit Sankey SRPT News & Why
ROARABLE RATING BRIEF • RQD 27/100 (E) ✓ SEC XBRL & RQD VERIFIED

SRPT — Sarepta Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Sarepta Therapeutics Inc. (SRPT) earns a live Roarable RQD composite score of 27/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $18.32 (-1.61% 1D, market capitalization $1.97B).

  • Fundamental Cash Engine (5/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 96.0%, operating margin of -37.5%, and free cash flow yield of -15.14%.
  • Whale 13F & Options Flow (8/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (3/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.20, Piotroski F-Score of 4/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Sarepta Therapeutics Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry. The profile does not describe its products, customers, or revenue model. Reported revenue was $1.86B for FY 2025 and $1.79B for FY 2024, with a gross margin of 96% per the market data.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Sarepta Therapeutics Inc. (SRPT) reported $1.86B in annual revenue (up from $1.79B in FY2024, +4.3% YoY) and -$713.4M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($1.14B revenue, -$536.0M net income) through FY2025, SRPT scaled operating cash flow to -$205.5M and free cash flow to -$307.5M, backed by $3.35B in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 27/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -15.14% and institutional whale pillar of 8/20. With Fundamental Cash Engine at 5/20 and Institutional Whale Flow at 8/20, sustained execution supports upside toward the upper end of the $14.68 – $24.68 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -37.5% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), SRPT carries a macro regime beta of 1.00 and gross margin of 96.0%.

  • Key Question #1: Can SRPT sustain or expand its -37.5% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $1.86B and free cash flow of -$307.5M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is SRPT's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

SRPT Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Sarepta Therapeutics Inc. (SRPT) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to SRPT Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

SRPT Bull vs. Bear Conversation Board — What's Your Call at $18.32?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SRPT 🐻 33% BEARISH CONVICTION
1. Pick Your Side on SRPT:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MA MacroHawk_NYC RQD DEBATE OPENER • Cross-Asset Macro Desk 🐂 BULLISH 🎯 Target: $22.16 (+19.0%)
📌 Pinned Debate

Institutional flow is scored at 11/20, the strongest pillar relative to weight, and the 96% gross margin indicates high revenue-level e

Don't sleep on SRPT's setup in Health Care. Institutional flow is scored at 11/20, the strongest pillar relative to weight, and the 96% gross margin indicates high revenue-level economics.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (27/100) backs up the fundamental quality.

SectorRotator 🐂 BULL

@MacroHawk_NYC Agree on the RQD 27/100 quality, though with 1.0 beta I'm scaling in with half-size at $18.62 and keeping dry powder in case we test $17.32.

SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH 🎯 Target: $14.90 (-20.0%)
Spot @ $18.62

Altman Z of 0.2, Piotroski F of 4/9, ROIC of -35%, and FCF yield of -15.14% signal a fragile balance sheet and cash-burning operations.

Fading this rally in SRPT at $18.62. Altman Z of 0.2, Piotroski F of 4/9, ROIC of -35%, and FCF yield of -15.14% signal a fragile balance sheet and cash-burning operations.. With a beta of 1.0 and the stock sitting at $18.62 (52-wk range $14.68–$24.68), the easy multiple expansion is already priced in.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%